Ken Griffin Adamis Pharmaceuticals Corp Transaction History

Citadel Advisors LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.1 - $0.3 $32,716 - $98,150	327,168 New	327,168 $39,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $0.54 $35,025 - $78,807	145,939 New	145,939 $29,000
Q1 2022 May 16, 2022	SELL	$0.55 - $0.73 $205,041 - $272,146	-372,803 Reduced 88.58%	48,048 $27,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.23 $188,145 - $405,998	330,080 Added 363.64%	420,851 $256,000
Q3 2021 Nov 15, 2021	BUY	$0.92 - $1.18 $62,997 - $80,801	68,476 Added 307.14%	90,771 $88,000

Q2 2021 Aug 16, 2021	SELL	$0.66 - $1.23 $89,179 - $166,197	-135,120 Reduced 85.84%	22,295 $24,000
Q1 2021 May 17, 2021	BUY	$0.54 - $1.79 $85,004 - $281,772	157,415 New	157,415 $148,000
Q2 2020 Aug 14, 2020	SELL	$0.33 - $0.66 $31,741 - $63,482	-96,185 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.33 - $0.89 $24,870 - $67,074	75,365 Added 361.98%	96,185 $34,000
Q2 2019 Aug 14, 2019	SELL	$1.26 - $2.23 $29,584 - $52,360	-23,480 Reduced 53.0%	20,820 $27,000
Q4 2018 Feb 14, 2019	SELL	$2.1 - $3.21 $63,707 - $97,381	-30,337 Reduced 40.65%	44,300 $99,000
Q3 2018 Nov 13, 2018	BUY	$2.25 - $4.8 $95,841 - $204,460	42,596 Added 132.94%	74,637 $0
Q2 2018 Aug 10, 2018	SELL	$3.2 - $4.7 $159,609 - $234,426	-49,878 Reduced 60.89%	32,041 $0
Q1 2018 May 11, 2018	SELL	$2.55 - $4.85 $13,499 - $25,675	-5,294 Reduced 6.07%	81,919 $287,000
Q4 2017 Feb 09, 2018	BUY	$3.5 - $5.65 $241,864 - $390,437	69,104 Added 381.6%	87,213 $384,000
Q3 2017 Nov 09, 2017	BUY	$4.5 - $5.65 $81,490 - $102,315	18,109	18,109 $95,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.